Control of insulin-like growth factor (IGF) action by regulation of IGF- I receptor expression

    Research output: Contribution to journalArticle

    18 Citations (Scopus)

    Abstract

    The insulin like growth factors (IGFs) control many aspects of growth, development and differentiation, and aberrant IGF action is implicated in a number of pathological states. Most of the actions of both IGF-I and IGF-II are mediated by their activation of the IGF-I receptor, a transmembrane tyrosine kinase that is structurally and functionally related to the insulin receptor. Control of the IGF-I receptor number at the cell surface is an important level at which IGF action can be regulated. Cell-surface receptor number, in turn, is principally determined by the level of expression of the IGF-I receptor gene. An important transcriptional regulatory factor that appears to be responsible for controlling IGF-I receptor gene expression is the product of the WT1 Wilms tumor suppressor gene. This latter protein functions by binding to specific sequences in the IGF-I receptor promoter and repressing transcription. During normal renal development, increased expression of the WT1 gene leads to repression of IGF-I receptor gene expression, allowing differentiation of the metanephrogenic blastema into renal epithelium. Persistent receptor expression due to mutational loss of WT1 function may contribute to the etiology of Wilms tumor. Decreased WT1 expression and subsequent up regulation of the IGF-I receptor has also been implicated in non-malignant proliferative disorders such as benign prostatic hyperplasia.

    Original languageEnglish (US)
    JournalEndocrine Journal
    Volume43
    Issue numberSUPPL.
    StatePublished - 1996

    Fingerprint

    IGF Type 1 Receptor
    Somatomedins
    Gene Expression
    Wilms' Tumor Genes
    Kidney
    Insulin-Like Growth Factor II
    Wilms Tumor
    Insulin Receptor
    Prostatic Hyperplasia
    Cell Surface Receptors
    Tumor Suppressor Genes
    Insulin-Like Growth Factor I
    Growth and Development
    Protein Binding
    Protein-Tyrosine Kinases
    Up-Regulation
    Epithelium
    Cell Count
    Genes

    Keywords

    • Gene regulation
    • IGF-I receptor
    • IGFs
    • Wilms tumor suppressor

    ASJC Scopus subject areas

    • Endocrinology

    Cite this

    Control of insulin-like growth factor (IGF) action by regulation of IGF- I receptor expression. / Roberts, Charles.

    In: Endocrine Journal, Vol. 43, No. SUPPL., 1996.

    Research output: Contribution to journalArticle

    @article{241df41ecf0a459b840d6acf7570dd58,
    title = "Control of insulin-like growth factor (IGF) action by regulation of IGF- I receptor expression",
    abstract = "The insulin like growth factors (IGFs) control many aspects of growth, development and differentiation, and aberrant IGF action is implicated in a number of pathological states. Most of the actions of both IGF-I and IGF-II are mediated by their activation of the IGF-I receptor, a transmembrane tyrosine kinase that is structurally and functionally related to the insulin receptor. Control of the IGF-I receptor number at the cell surface is an important level at which IGF action can be regulated. Cell-surface receptor number, in turn, is principally determined by the level of expression of the IGF-I receptor gene. An important transcriptional regulatory factor that appears to be responsible for controlling IGF-I receptor gene expression is the product of the WT1 Wilms tumor suppressor gene. This latter protein functions by binding to specific sequences in the IGF-I receptor promoter and repressing transcription. During normal renal development, increased expression of the WT1 gene leads to repression of IGF-I receptor gene expression, allowing differentiation of the metanephrogenic blastema into renal epithelium. Persistent receptor expression due to mutational loss of WT1 function may contribute to the etiology of Wilms tumor. Decreased WT1 expression and subsequent up regulation of the IGF-I receptor has also been implicated in non-malignant proliferative disorders such as benign prostatic hyperplasia.",
    keywords = "Gene regulation, IGF-I receptor, IGFs, Wilms tumor suppressor",
    author = "Charles Roberts",
    year = "1996",
    language = "English (US)",
    volume = "43",
    journal = "Endocrine Journal",
    issn = "0918-8959",
    publisher = "Japan Endocrine Society",
    number = "SUPPL.",

    }

    TY - JOUR

    T1 - Control of insulin-like growth factor (IGF) action by regulation of IGF- I receptor expression

    AU - Roberts, Charles

    PY - 1996

    Y1 - 1996

    N2 - The insulin like growth factors (IGFs) control many aspects of growth, development and differentiation, and aberrant IGF action is implicated in a number of pathological states. Most of the actions of both IGF-I and IGF-II are mediated by their activation of the IGF-I receptor, a transmembrane tyrosine kinase that is structurally and functionally related to the insulin receptor. Control of the IGF-I receptor number at the cell surface is an important level at which IGF action can be regulated. Cell-surface receptor number, in turn, is principally determined by the level of expression of the IGF-I receptor gene. An important transcriptional regulatory factor that appears to be responsible for controlling IGF-I receptor gene expression is the product of the WT1 Wilms tumor suppressor gene. This latter protein functions by binding to specific sequences in the IGF-I receptor promoter and repressing transcription. During normal renal development, increased expression of the WT1 gene leads to repression of IGF-I receptor gene expression, allowing differentiation of the metanephrogenic blastema into renal epithelium. Persistent receptor expression due to mutational loss of WT1 function may contribute to the etiology of Wilms tumor. Decreased WT1 expression and subsequent up regulation of the IGF-I receptor has also been implicated in non-malignant proliferative disorders such as benign prostatic hyperplasia.

    AB - The insulin like growth factors (IGFs) control many aspects of growth, development and differentiation, and aberrant IGF action is implicated in a number of pathological states. Most of the actions of both IGF-I and IGF-II are mediated by their activation of the IGF-I receptor, a transmembrane tyrosine kinase that is structurally and functionally related to the insulin receptor. Control of the IGF-I receptor number at the cell surface is an important level at which IGF action can be regulated. Cell-surface receptor number, in turn, is principally determined by the level of expression of the IGF-I receptor gene. An important transcriptional regulatory factor that appears to be responsible for controlling IGF-I receptor gene expression is the product of the WT1 Wilms tumor suppressor gene. This latter protein functions by binding to specific sequences in the IGF-I receptor promoter and repressing transcription. During normal renal development, increased expression of the WT1 gene leads to repression of IGF-I receptor gene expression, allowing differentiation of the metanephrogenic blastema into renal epithelium. Persistent receptor expression due to mutational loss of WT1 function may contribute to the etiology of Wilms tumor. Decreased WT1 expression and subsequent up regulation of the IGF-I receptor has also been implicated in non-malignant proliferative disorders such as benign prostatic hyperplasia.

    KW - Gene regulation

    KW - IGF-I receptor

    KW - IGFs

    KW - Wilms tumor suppressor

    UR - http://www.scopus.com/inward/record.url?scp=0030443672&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0030443672&partnerID=8YFLogxK

    M3 - Article

    C2 - 9076342

    AN - SCOPUS:0030443672

    VL - 43

    JO - Endocrine Journal

    JF - Endocrine Journal

    SN - 0918-8959

    IS - SUPPL.

    ER -